0001144204-19-045298.txt : 20190919 0001144204-19-045298.hdr.sgml : 20190919 20190919191221 ACCESSION NUMBER: 0001144204-19-045298 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190917 FILED AS OF DATE: 20190919 DATE AS OF CHANGE: 20190919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lewis-Hall Freda C CENTRAL INDEX KEY: 0001437909 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39044 FILM NUMBER: 191102465 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc. CENTRAL INDEX KEY: 0001773427 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-883-9490 MAIL ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 4 1 tv529791_form4.xml FORM 4 X0306 4 2019-09-17 0 0001773427 SpringWorks Therapeutics, Inc. SWTX 0001437909 Lewis-Hall Freda C C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD. STAMFORD CT 06902 1 0 1 0 Common Stock 2019-09-17 4 C 0 978194 A 978194 I By: Pfizer Inc. Common Stock 2019-09-17 4 C 0 3039051 A 4017245 I By: Pfizer Inc. Common Stock 2019-09-17 4 C 0 526602 A 4543847 I By: Pfizer Ventures (US) LLC Common Stock 2019-09-17 4 P 0 50000 18 A 4593847 I By: Pfizer Ventures (US) LLC Junior Series A Convertible Preferred Stock 2019-09-17 4 C 0 978194 D Common Stock 978194 0 I By: Pfizer Inc. Series A Convertible Preferred Stock 2019-09-17 4 C 0 3039051 D Common Stock 3039051 0 I By: Pfizer Inc. Series B Convertible Preferred Stock 2019-09-17 4 C 0 526602 D Common Stock 526602 0 I By: Pfizer Ventures (US) LLC Each share of Junior Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Junior Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Junior Series A Convertible Preferred Stock has no expiration date. Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock has no expiration date. Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. Shares held by Pfizer Inc. ("Pfizer"). The reporting person is employed by Pfizer. The reporting person has no voting or dispositive power over the shares held by Pfizer or Pfizer Ventures (US) Holdings ("Pfizer Ventures"), a wholly owned subsidiary of Pfizer, and disclaims beneficial ownership of all such shares. Shares held by Pfizer Ventures. The reporting person is employed by Pfizer. The reporting person has no voting or dispositive power over the shares held by Pfizer or Pfizer Ventures and disclaims beneficial ownership of all such shares. /s/ Michael V. Greco, Attorney-in-Fact 2019-09-19